> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pfizer Raises 2026 Revenue Forecast By $1.5 Billion At The Midpoint As Eliquis Jumps 25%
- URL: https://www.bullished.co/pfizer-raises-2026-revenue-forecast-by-1-5-billion-at-the-midpoint-as-eliquis-jumps-25-275399de/
- Published: 2026-11-03T13:16:46.000Z
- Updated: 2026-11-03T13:16:46.000Z
- Description: Third-quarter sales were flat at $16.6 billion as Eliquis and cancer drugs offset a 63% Paxlovid drop, and Pfizer named a new CFO.
- Author: Matteo Parrino
- Tags: Earnings, PFE, Industry: Healthcare

Pfizer, the maker of Eliquis, Ibrance and Comirnaty, [raised its full-year 2026 revenue forecast by $1.5 billion at the midpoint](https://www.sec.gov/Archives/edgar/data/0000078003/000007800326000125/pfe-9272026xex99.htm?ref=bullished.co), to $62.0 billion to $64.0 billion, after third-quarter sales held roughly flat. The company also lifted its adjusted earnings guidance and named Cecile Guegan chief financial officer, it said Tuesday.

## A flat quarter with a split inside

Third-quarter revenue was $16.6 billion, relatively flat operationally against a year earlier. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally, and launched and acquired products grew 32% operationally, [the company reported](https://www.businesswire.com/news/home/20261103921895/en/Pfizer-Reports-Strong-Third-Quarter-2026-Results-And-Raises-2026-Guidance?ref=bullished.co).

Eliquis sales rose 25% operationally, up $513 million, helped by higher net price in the U.S. from lower rebates and channel mix, plus higher demand globally. Padcev climbed 55%, Lorbrena 43% and the Vyndaqel family 12%.

Paxlovid fell 63% operationally, down $771 million, on lower Covid infections. Comirnaty dropped 29%, and the Prevnar family slipped 10%.

Reported net income fell 8% to [$3,242 million](https://www.businesswire.com/news/home/20261103921895/en/Pfizer-Reports-Strong-Third-Quarter-2026-Results-And-Raises-2026-Guidance?ref=bullished.co), or $0.56 per diluted share. Adjusted earnings were $0.87 per share, unchanged from a year earlier.

## The new guidance and its $650 million charge

Pfizer raised and narrowed adjusted earnings per share guidance to [$2.95 to $3.05](https://www.cnbc.com/2026/11/03/pfizer-pfe-earnings-q3-2026.html?ref=bullished.co), from $2.80 to $3.00\. That range already includes a one-time $650 million acquired research charge, booked in the third quarter, for the licensing and collaboration deal with Innovent Biologics, worth about $0.10 per share.

The company expects an unfavorable revenue hit of about $1.1 billion from generic and biosimilar competition. Guidance assumes no share repurchases in 2026.

Guegan, whose appointment took effect November 1, said the company is raising guidance to reflect "strong year-to-date performance and confidence in our business."

## Nine-month profit tells a weaker story

For the first nine months, reported net income fell 40% to $5,681 million. Asset impairments of $4,325 million weighed on it, including $3.8 billion tied to unfavorable Phase 3 lung cancer trial results for sigvotatug vedotin. A $1,870 million gain on the sale of its ViiV stake partly offset them. Nine-month revenue rose 2% to $46,067 million.

Pfizer paid $7.3 billion in dividends over the period and completed no buybacks. Its remaining repurchase authorization is $3.3 billion.

Pfizer holds its earnings call and webcast at 10:00 a.m. ET Tuesday, and CEO Albert Bourla pointed to a slate of late-stage pipeline catalysts ahead.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — PFIZER INC (PFE)](https://www.sec.gov/Archives/edgar/data/0000078003/000007800326000125/pfe-20261103.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit pfe-9272026xex99.htm — PFIZER INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000078003/000007800326000125/pfe-9272026xex99.htm?ref=bullished.co) — SEC EDGAR
- [Pfizer (PFE) earnings Q3 2026](https://www.cnbc.com/2026/11/03/pfizer-pfe-earnings-q3-2026.html?ref=bullished.co) — CNBC
- [Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance](https://www.businesswire.com/news/home/20261103921895/en/Pfizer-Reports-Strong-Third-Quarter-2026-Results-And-Raises-2026-Guidance?ref=bullished.co) — businesswire.com